OBR Daily Commentary

forumImage

Researchers Uncover Major Clue In Predicting Response To Immunotherapy

(Forbes) Jan 14, 2019 - Researchers at Memorial Sloan Kettering Cancer Center in New York have discovered that cancer cells with high numbers of faults in their DNA are more likely to respond to immune checkpoint inhibitors (ICI), a major class of immunotherapy drugs, which includes Keytruda. The study, published today in Nature Genetics adds important pieces to the puzzle as to why some cancer patients respond to immunotherapy whereas others do not. The researchers measured 'tumor mutation burden (TMB)', essentially counting how many DNA faults a tumor contains by looking for errors in the DNA sequence.

Read Article arrow

Tomasz M. Beer, MD, FACP (Posted: January 14, 2019)

quotesIt is fascinating to see that greater complexity of cancer, typically associated with more aggressive behavior and greater resistance to conventional therapies, may be helpful in immunotherapy responsiveness.quotes

Add Comment 1 Comment
forumImage

Physician Burnout -- These Characters Are To Blame

(Forbes) Jan 10, 2019 - Physician burnout in the U.S. is reaching epidemic levels, affecting the majority of physicians in some specialties.

Read Article arrow

Tomasz M. Beer, MD, FACP (Posted: January 10, 2019)

quotesWe must take burnout seriously if we are to retain a robust physician work force. I would offer one observation. The discussion of physician burnout often occurs in a vacuum. We need to recognize that burnout is increasing in many segments of society. It is not a unique ailment limited to the medical profession. And we would be wise to consider the impact of technology, social media, and the resulting 24/7 work cycle on humanity. Many of the changes that we face have emerged rapidly and their full effect is just beginning to be recognized.quotes

Add Comment 1 Comment
forumImage

Astellas and Pfizer Announce Positive Top-Line Results from Phase 3 ARCHES Trial of XTANDI® (enzalutamide) in Men with Metastatic Hormone-Sensitive Prostate Cancer

(Astellas) Dec 20, 2018 - Astellas Pharma Inc. and Pfizer Inc. today announced that the Phase 3 ARCHES trial evaluating XTANDI® (enzalutamide) plus androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC) met its primary endpoint, significantly improving radiographic progression-free survival (rPFS) versus ADT alone.

Read Article arrow

Tomasz M. Beer, MD, FACP (Posted: December 20, 2018)

quotesIntensification of therapy for newly diagnosed metastatic prostate cancer has become standard of care as a result of positive results with docetaxel and with abiraterone. It is not unexpected, therefore, that a similar approach with enzalutamide would yield favorable results. We will await eagerly the detailed results to better understand the effect of this combination.quotes

Add Comment 1 Comment

Meet the Editorial Board

Prostate Cancer
member photo
Tomasz M. Beer, MD, FACP

Professor of Medicine, Division of Hematology/Medical O...

Community Oncology
member photo
Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology...

Breast Cancer
member photo
Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncol...

Lung Cancer
member photo
H. Jack West, MD

Medical Director, Thoracic Oncology Program, Swedish Ca...

Gastrointestinal Cancers
member photo
Howard S. Hochster, MD

Distinguished Professor of Medicine, Rutgers Robert Woo...

Radiation Oncology
member photo
Howard Sandler, MD, MS, FASTRO

Ronald H. Bloom Chair in Cancer Therapeutics
Pr...

Community Oncology
member photo
Jeff Patton, M.D.

CEO Tennessee Oncology...

Precision Medicine Section Editor
member photo
Jennifer Levin Carter, MD, MPH

Chief Medical Officer and Founder, N-of-One...

Financial Sector
member photo
Michael G. King Jr.

Managing Director and Senior Biotechnology Analyst...

Gastrointestinal Cancers
member photo
Richard Goldberg, MD

Director WVU Cancer Institute Director of Cancer Signa...

Editor-In-Chief
member photo
Robert A. Figlin, MD., FACP

Professor and Director, Division of Hematology Oncology...

Health Policy
member photo
Ted Okon

Executive Director Community Oncology Alliance...

Community Oncology
member photo
Thomas Marsland, MD

Vice President Integrated Community Oncology Network ...

Community Oncology
member photo
William Harwin MD

Florida Cancer Specialists President and Managing Part...

Health Policy
member photo
William McGivney, PhD

National Health Policy Expert...

Payer
member photo
Winston Wong, PharmD

President, W-Squared Group...